5,274 Shares in Insulet Corporation $PODD Purchased by Caprock Group LLC

Caprock Group LLC purchased a new stake in Insulet Corporation (NASDAQ:PODD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,274 shares of the medical instruments supplier’s stock, valued at approximately $1,793,000.

Other large investors have also modified their holdings of the company. Sage Mountain Advisors LLC boosted its stake in shares of Insulet by 4.6% during the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 33 shares during the last quarter. Curi Capital LLC lifted its stake in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares during the period. Evelyn Partners Investment Management Services Ltd boosted its position in Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after acquiring an additional 39 shares during the last quarter. PDS Planning Inc grew its stake in Insulet by 5.1% in the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock worth $253,000 after acquiring an additional 40 shares during the period. Finally, Camarda Financial Advisors LLC raised its holdings in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares during the last quarter.

Insulet Price Performance

Shares of PODD stock opened at $242.74 on Friday. The firm has a fifty day moving average of $277.19 and a two-hundred day moving average of $306.27. The firm has a market cap of $17.08 billion, a P/E ratio of 70.36, a P/E/G ratio of 1.36 and a beta of 1.41. Insulet Corporation has a 1-year low of $230.05 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Wall Street Analyst Weigh In

PODD has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered their target price on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Zacks Research downgraded Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Canaccord Genuity Group lifted their target price on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Barclays upped their price target on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, TD Cowen lowered Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective on the stock. in a research note on Monday, January 26th. Twenty investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus target price of $374.10.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.